Clinical Trials

Parkinson Disease 4, Autosomal Dominant Lewy Body, Thymoma

NCT04428151 2025-12-04

LEAP-009

408 enrolled 17 charts

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT04704219 2025-12-03

KEYNOTE-B61

160 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04165083 2025-11-26

MK-3475-01B

102 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03797326 2025-11-17

LEAP-005

BreastCNSGastrointestinalGynecologic

611 enrolled 27 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02628067 2025-09-22

KEYNOTE 158

Phase 2 Active not recruiting

1,609 enrolled 5 FDA

EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

NCT06307431 2025-09-02

INTerpath-004

Phase 2 Active not recruiting

272 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT03322540 2025-08-22

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

154 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

613 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT04116073 2025-07-29

INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer

25 enrolled 12 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT04924101 2025-07-23

KEYNOTE-B99

126 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT03516981 2025-07-01

MK-3475-495

245 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT04165096 2025-06-25

MK-3475-01C

128 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03631784 2025-03-25

KEYNOTE-799

216 enrolled 15 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02787005 2024-11-21

KEYNOTE-199

388 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03631407 2024-11-21

MK-7690-046

41 enrolled 20 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT02702414 2024-09-04

KEYNOTE-224

156 enrolled 17 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT03284424 2024-08-23

MK-3475-629

159 enrolled 16 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Squamous Cell

NCT03664024 2024-08-22

KEYNOTE-782

118 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT04152863 2024-08-06

V937-011

Phase 2 Terminated

85 enrolled 19 charts

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05626569 2024-01-03

Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC

40 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04271384 2023-12-26

Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer

25 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02460198 2023-07-27

KEYNOTE-164

124 enrolled 15 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT02576990 2023-07-27

MK-3475-170

80 enrolled 19 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT05941338 2023-07-12

HNC-SYSU-001

Phase 2 Recruiting

100 enrolled

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Mouth Neoplasms

NCT02853344 2023-04-11

MK-3475-427

275 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT02335424 2023-03-02

MK-3475-052

374 enrolled 37 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT05386056 2022-11-28

Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma

54 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT02559687 2022-09-14

KEYNOTE-180

121 enrolled 14 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT05519202 2022-08-29

Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer

47 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT04749394 2022-08-16

A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy

42 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02335411 2022-08-08

KEYNOTE-059

318 enrolled 24 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT02968940 2022-06-29

Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma

6 enrolled 10 charts

CNS

Parkinson Disease 4, Autosomal Dominant Lewy Body, Glioblastoma, Glioma

NCT02255097 2022-06-28

Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)

172 enrolled 27 charts

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT04812002 2022-06-03

Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy

Phase 2 Recruiting

20 enrolled

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Gestational Trophoblastic Disease

NCT05392686 2022-05-26

PD1 and PARP for Maintenance Therapy in NSLLC

52 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT03753243 2022-04-20

Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

Phase 2 Recruiting

32 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT02674061 2022-03-24

KEYNOTE-100

376 enrolled 102 charts

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Ovarian Neoplasms

NCT02549209 2022-03-02

Pembro/Carbo/Taxol in Endometrial Cancer

46 enrolled 13 charts

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT03322566 2022-01-24

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

233 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02447003 2020-12-16

Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)

254 enrolled 22 charts

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT04530227 2020-11-13

Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC